GALMED PHARMACEUTICALS LTD. (GLMD)

Every figure this model derived for GLMD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2020-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2022-12-31
cash 10,985,000 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 18,627,000 AssetsCurrent 2025-12-31
current liabilities 2,845,000 LiabilitiesCurrent 2025-12-31
equity 15,782,000 StockholdersEquity 2025-12-31
revenue 0 Revenues 2020-12-31
sbc 0 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up GLMD on one particular measure came for.

RatioValue
current ratio6.55
current ratio reported6.55
deferred revenue growth-100.0
growth cv2.51
roic-497.52

What to be careful about

What this model itself distrusts about GLMD's figures. Written by the derivation as it ran, not added afterwards.